Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02992483 |
| Title | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ITA | FRA | ESP | DEU | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| MD Anderson Cancer Center/University of Texas MD Anderson CC | Houston | Texas | 77030 | United States | Details | |
| Novartis Investigative Site | Heidelberg | Victoria | 3084 | Australia | Details | |
| Novartis Investigative Site | Nantes Cedex 1 | 44093 | France | Details | ||
| Novartis Investigative Site | Heidelberg | 69120 | Germany | Details | ||
| Novartis Investigative Site | Kiel | 24105 | Germany | Details | ||
| Novartis Investigative Site | Rozzano | MI | 20089 | Italy | Details | |
| Novartis Investigative Site | Fukuoka-city | Fukuoka | 811-1395 | Japan | Details | |
| Novartis Investigative Site | Salamanca | Castilla Y Leon | 37007 | Spain | Details |